Anil Raghavan Appointed As CEO & MD Of Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company (SPARC) Limited has appointed Anil Raghavan as Chief Executive Officer and Managing Director (CEO & MD), effective August 11, 2026, subject to shareholder approval.
Raghavan, who currently serves as CEO of SPARC, will take over the role following the retirement of Dr. Rajamannar Thennati from the Board after completing his term at the company’s 21st Annual General Meeting (AGM) on August 10, 2026.
Raghavan has served as CEO of SPARC since April 2014 and has led initiatives focused on business growth, strategic partnerships, and research development. Before joining SPARC, he was MD of Quintiles’ India and Sri Lanka business, where he was part of the global leadership team. Earlier, he worked with consulting firms including Arthur Andersen, KPMG, and Cambridge Technology Partners, advising companies on strategy and performance improvement. He is a pharmaceutical services executive with experience in business strategy, operations, and healthcare consulting. He has also contributed to industry discussions and serves on the Advisory Board of Medwell Ventures Pvt. Ltd. Raghavan holds a B.Tech. Degree in Industrial Engineering from the University of Kerala.




